IMPL Impel NeuroPharma Inc.

18
+3.02  (+20%)
Previous Close 14.98
Open 15.3
52 Week Low 6.904
52 Week High 15.89
Market Cap $400,972,878
Shares 22,276,271
Float 9,874,620
Enterprise Value $325,733,370
Volume 118,013
Av. Daily Volume 82,026
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
INP104 (Dihydroergotamine)
Migraine
PDUFA
PDUFA
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
INP105 (Olanzapine)
Acute Agitation
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
INP107 (Levodopa/Carbidopa)
Morning OFF Episodes in Parkinson’s
Phase 1
Phase 1
Phase 1 trial completed. PK study for pivotal dose selection to be initiated in 2022.

Latest News

  1. SEATTLE, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ:IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced that Adrian Adams, chief executive officer, will present on a panel titled "For Headaches THIS Big – The Evolution of Migraine Therapeutic Landscape" at the 2021 Wedbush Pacgrow Virtual Healthcare Conference on Tuesday, August 10, 2021 at 8:00-8:30 a.m. ET.

    The conference will not be webcasting this panel discussion.

    About Impel NeuroPharma

    Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary…

    SEATTLE, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ:IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced that Adrian Adams, chief executive officer, will present on a panel titled "For Headaches THIS Big – The Evolution of Migraine Therapeutic Landscape" at the 2021 Wedbush Pacgrow Virtual Healthcare Conference on Tuesday, August 10, 2021 at 8:00-8:30 a.m. ET.

    The conference will not be webcasting this panel discussion.

    About Impel NeuroPharma

    Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company's strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson's disease.

    Investor Relations:

    Christina Tartaglia

    Stern Investor Relations

    Phone: (1) 212-362-1200

    Email: 

    Media Relations:

    Melyssa Weible

    Elixir Health Public Relations

    Phone: (1) 201-723-5805

    Email:



    Primary Logo

    View Full Article Hide Full Article
  2. SEATTLE, July 29, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ:IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced that it will host a virtual key opinion leader (KOL) event to review the post triptan failure landscape and new options for the treatment of acute migraine. In addition, the program will cover the role of non-oral acute migraine therapies, including the history of use of dihydroergotamine (DHE), the STOP301 trial results for Impel's lead product candidate TRUDHESA™ and commercial insights and opportunities in the acute migraine market. The…

    SEATTLE, July 29, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ:IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced that it will host a virtual key opinion leader (KOL) event to review the post triptan failure landscape and new options for the treatment of acute migraine. In addition, the program will cover the role of non-oral acute migraine therapies, including the history of use of dihydroergotamine (DHE), the STOP301 trial results for Impel's lead product candidate TRUDHESA™ and commercial insights and opportunities in the acute migraine market. The event will take place on Friday, August 6, 2021 at 1:00pm ET.

    The event will feature presentations from guest speakers Dr. Wade Cooper, Director of Headache and Neuropathic Pain at the University of Michigan School of Medicine, Dr. Stewart Tepper, Director of Dartmouth Headache Center at the Geisel School of Medicine, Dr. Nada Hindiyeh, Assistant Professor of neurology and neurological systems at Stanford Medical School and Impel NeuroPharma management.

    A live webcast of the event will be available on the Investors section of the Impel NeuroPharma website at https://investors.impelnp.com/. A replay of the webcast and accompanying slides will be available on the Impel NeuroPharma website following the event.

    About Impel NeuroPharma

    Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company's strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson's disease.

    Investor Relations:

    Christina Tartaglia

    Stern Investor Relations

    Phone: (1) 212-362-1200

    Email: 

    Media Relations:

    Melyssa Weible

    Elixir Health Public Relations

    Phone: (1) 201-723-5805

    Email:



    Primary Logo

    View Full Article Hide Full Article
  3. SEATTLE, July 07, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (Impel), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced the closing of a $50 million debt facility with Oxford Finance LLC and Silicon Valley Bank, of which the first $20 million was funded at closing.

    "This strategic debt financing, coupled with our current cash, increases our balance sheet strength and firmly positions us to execute upon the potential launch and commercialization of TRUDHESA™ for the treatment of patients with acute migraine," said Adrian Adams, chairman and chief executive officer…

    SEATTLE, July 07, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (Impel), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced the closing of a $50 million debt facility with Oxford Finance LLC and Silicon Valley Bank, of which the first $20 million was funded at closing.

    "This strategic debt financing, coupled with our current cash, increases our balance sheet strength and firmly positions us to execute upon the potential launch and commercialization of TRUDHESA™ for the treatment of patients with acute migraine," said Adrian Adams, chairman and chief executive officer of Impel NeuroPharma. "The TRUDHESA NDA was accepted for review by the U.S. Food and Drug Administration in January of this year and has a Prescription Drug User Fee Act target action date of September 6, 2021."

    The initial $20 million tranche extends Impel's expected cash runway through the 4th quarter of 2022. Under the terms of the debt facility, the second $10 million tranche is available through September 30, 2021 upon the approval of TRUDHESA™. The third $20 million tranche is available through December 31, 2022, upon the achievement of certain revenue milestones and other specified conditions. The debt facility will mature on July 1, 2026 and requires interest only payments until September 1, 2023, subject to potential extension with achievement of certain revenue milestones.

    "Oxford and SVB are pleased to provide Impel with access to this growth capital term loan facility as the Company prepares to commercially launch TRUDHESA™ and continues to develop its proprietary POD® technology, which has demonstrated successful results in multiple clinical trials to date," said Christopher Herr, Senior Managing Director at Oxford.

    Cowen acted as the Company's sole financial adviser in connection with the debt facility.

    About Impel NeuroPharma

    Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company's strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson's disease.

    About Oxford Finance LLC

    Oxford Finance is a specialty finance firm providing senior secured loans to public and private life sciences and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over $7 billion in loans, with lines of credit ranging from $5 million to $150 million. Oxford is headquartered in Alexandria, Va., with additional offices in San Diego, Calif.; Palo Alto, Calif.; and the greater Boston and New York City areas. For more information, visit https://oxfordfinance.com/

    About Silicon Valley Bank

    For nearly 40 years, Silicon Valley Bank (SVB) has helped innovative companies and their investors move bold ideas forward, fast. SVB provides targeted financial services and expertise through its offices in innovation centers around the world, including offices in Seattle, San Francisco, Irvine and San Diego. With commercial, international and private banking services, SVB helps address the unique needs of innovators. Learn more at svb.com.

    Cautionary Note on Forward-Looking Statements

    This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, expectations regarding Impel's cash runway, Impel's ability to satisfy the conditions for additional tranches of the debt facility, the timing of approval of Impel's NDA for INP104 (proposed trade name TRUDHESA™) and of Impel's other regulatory submissions, timing of announcements of clinical results and clinical development activities of its product candidates and potential benefits and market opportunities of INP104 and its other product candidates. Forward-looking statements can be identified by words such as: "believe," "may," "will," "potentially," "estimate," "continue," "anticipate," "intend," "could," "would," "project," "plan," "expect" or the negative or plural of these words or similar expressions. These statements are subject to numerous risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including but not limited to, Impel's ability to obtain and maintain regulatory approval of INP104 and its other product candidates, its ability to execute its commercialization strategy for INP104 its ability to develop, manufacture and commercialize its product candidates including plans for future development of its POD devices and plans to address additional indications for which Impel may pursue regulatory approval, whether results of preclinical studies or clinical trials will be indicative of the results of future trials, and the effects of COVID-19 on its clinical programs and business operations. Many of these risks are described in greater detail in Impel's filings with the Securities and Exchange Commission. Any forward-looking statements in this press release speak only as of the date of this press release. Impel assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

    Impel, POD and the Impel logo are U.S. registered trademarks of Impel NeuroPharma, Inc. To learn more about Impel NeuroPharma, please visit our website at https://impelnp.com/.

    Contact:

    Investor Relations:

    Christina Tartaglia

    Stern Investor Relations

    Phone: (1) 212-362-1200

    Email: 

    Media Relations:

    Melyssa Weible

    Elixir Health Public Relations

    Phone: (1) 201-723-5805

    Email:



    Primary Logo

    View Full Article Hide Full Article
  4. SEATTLE, June 16, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced that the Company will present a corporate overview at the Raymond James Human Health Innovations Conference on Wednesday, June 23, 2021 at 3:20 p.m. ET.

    A live webcast, if recorded, of the presentation can be accessed under "News & Events" in the Investors section of the Company's website at https://investors.impelnp.com/investor-relations. The archived webcast will be available on the Company's website shortly after the event.

    About Impel NeuroPharma

    SEATTLE, June 16, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced that the Company will present a corporate overview at the Raymond James Human Health Innovations Conference on Wednesday, June 23, 2021 at 3:20 p.m. ET.

    A live webcast, if recorded, of the presentation can be accessed under "News & Events" in the Investors section of the Company's website at https://investors.impelnp.com/investor-relations. The archived webcast will be available on the Company's website shortly after the event.

    About Impel NeuroPharma

    Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company's strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson's disease.

    Contact

    Investor Relations:

    Christina Tartaglia

    Stern Investor Relations

    Phone: (1) 212-362-1200

    Email: 

    Media Relations:

    Melyssa Weible

    Elixir Health Public Relations

    Phone: (1) 201-723-5805

    Email: 



    Primary Logo

    View Full Article Hide Full Article
  5. – Completed successful IPO raising approximately $80.0 million in gross proceeds –
    – NDA for TRUDHESA for treatment of acute migraine accepted for review by FDA; PDUFA date of September 6, 2021 –
    – Strengthened commercial capabilities with expanded management team and strategic collaboration with Veeva Systems –

    SEATTLE, June 07, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ:IMPL), a late-stage pharmaceutical company focused on utilizing its proprietary POD® technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2021 and produced a recent business update.

    "The past quarter and recent…

    – Completed successful IPO raising approximately $80.0 million in gross proceeds –

    – NDA for TRUDHESA for treatment of acute migraine accepted for review by FDA; PDUFA date of September 6, 2021 –

    – Strengthened commercial capabilities with expanded management team and strategic collaboration with Veeva Systems –

    SEATTLE, June 07, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ:IMPL), a late-stage pharmaceutical company focused on utilizing its proprietary POD® technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2021 and produced a recent business update.

    "The past quarter and recent months were marked by significant financial and clinical milestones for Impel as we execute on what we believe will be a transformational year for the Company. With the completion of a successful IPO, we are well-financed as we approach the potential launch of TRUDHESA, a treatment option for patients with migraines, later this year," said Adrian Adams, chairman and chief executive officer of Impel NeuroPharma. "Additionally, we have continued the disciplined build-out of our commercial infrastructure, by the addition of key, experienced hires with considerable track records of success, in addition to engaging in a strategic collaboration with Veeva to broaden our commercial capabilities."

    First Quarter and Recent Business Highlights

    • Completed initial public offering (IPO), raising approximately $80.0 million in gross proceeds. In April, Impel announced it had closed its initial public offering of 5,333,334 common shares at a price to the public of $15.00 per share. With completion of the IPO, the Company believes it has sufficient financial resources to fund operations through mid-2022.



    • FDA PDUFA date set for September 6, 2021. In January 2021, U.S. Food and Drug Administration (FDA) accepted for review the Company's 505(b)(2) New Drug Application (NDA) for TRUDHESA for the acute treatment of migraine headaches with or without aura in adults. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of September 6, 2021. The NDA submission for TRUDHESA is supported by safety results from the pivotal Phase 3 STOP 301 study, which met its primary objectives, with no new safety signals or concerning trends in nasal safety findings observed for TRUDHESA. TRUDHESA, if approved by the FDA, will become the first and only therapy to utilize the POD technology, a novel delivery system that specifically targets the vascular-rich upper nasal space.



    • Expanded management team with key, experienced hires to further enhance commercial execution, infrastructure, and market access capabilities as Company advances toward commercialization. In March 2021, the Company appointed Leonard S. Paolillo as Chief Commercial Officer, and Gerald F. Penn as Vice President, Market Access and Trade. Mr. Paolillo and Mr. Penn bring a wealth of commercial strategy and product launch experience in competitive and complex markets.



    • Engaged in strategic collaboration with Veeva to build integrated, digital-first commercial foundation. In February 2021, Impel announced a collaboration on key pre-launch preparations for TRUDHESA with Veeva Commercial Cloud, which will provide a complete commercial suite of data, software, and consulting services to drive its strategy and accelerate field engagement. This collaboration will help design and implement customer-centric strategies that will enable Impel sales professionals to increase the value of their targeted interactions with healthcare professionals.

    First Quarter 2021 Financial Results:

    • Research and Development (R&D) Expenses: Research and development expenses for the first quarter of 2021 were $4.1 million, which compares with $6.4 million for the first quarter of 2020. The decrease in R&D spending was due primarily to a decrease in clinical costs post the completion of the TRUDHESA Phase 3 trial.



    • General and Administrative (G&A) Expenses: General and administrative expenses for the first quarter of 2021 were $5.8 million, which compares with $3.5 million for the first quarter of 2020. The increase in G&A was due primarily to the ramp up of commercial related activity in preparation for the potential approval (and subsequent launch) of TRUDHESA.



    • Net Loss: For the first quarter of 2021, Impel reported a net loss of $11.4 million, compared to a net loss of $9.9 million for the same period in 2020.  



    • Non-GAAP Net Loss Per Share: Non-GAAP Net Loss Per Share was $0.54 for the first quarter of 2021, and $0.54 for the first quarter of 2020. Non-GAAP Pro Forma Net Loss Per Share gives effect to our reverse stock split, the shares of common stock issued in our IPO, and the conversion of our convertible preferred stock and our convertible notes into shares of common stock as if such conversions occurred at the beginning of each period presented. Non-GAAP Net Loss Per Share excludes the effect of accretion on our redeemable convertible preferred stock and interest expense on our convertible notes, all of which converted to shares of common stock in our April 2021 IPO. Please refer to the section in this press release titled "Reconciliation of GAAP and Non-GAAP Results" for details.



    • GAAP Net Loss Per Share: GAAP Net Loss Per Share totaled $15.09 per share in the first quarter of 2021 and $27.40 in the first quarter of 2020. The weighted average share count used in our GAAP net loss per share calculations does not reflect the issuance of 5.3 million shares of common stock in our IPO, 0.6 million shares upon the April 2021 conversion of our convertible notes, 0.05 million shares upon conversion of net exercised warrants, and 12.6 million shares upon the April 2021 conversion of our preferred stock.



    • Cash Balance: As of March 31, 2021, the Company had cash and cash equivalents of $4.4 million, and the Company had cash and cash equivalents of $71.1m as of April 30, 2021, post the April IPO.

    Non-GAAP Financial Measures

    We have provided in this press release certain financial information that has not been prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). Our management uses these non-GAAP financial measures internally in analyzing our financial results and believes that use of these non-GAAP financial measures is useful to investors as an additional tool to evaluate ongoing operating results and trends and in comparing our financial results with other companies in our industry, many of which present similar non-GAAP financial measures. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable financial measures prepared in accordance with GAAP and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP. A reconciliation of our historical non-GAAP financial measures to the most directly comparable GAAP measures has been provided in the financial statement tables included in this press release, and investors are encouraged to review these reconciliations.

    About TRUDHESA™:

    TRUDHESA™, the Company's lead product candidate, aims to optimize dihydroergotamine mesylate (DHE) for fast and lasting whole migraine relief, regardless of when in the migraine attack it is administered, without an injection. Importantly, TRUDHESA™ is designed to deliver a lower dose of DHE compared to other nasally administered, FDA-approved and investigational products. This may enable patients to benefit from the established efficacy of DHE, without the undesired side effects that may be experienced with delivery to the lower nasal space.

    TRUDHESA™ utilizes Impel's propellant-enabled POD technology to conveniently and consistently deliver optimal doses of DHE directly into the vascular rich upper nasal space, an ideal target for efficient drug administration. This may be particularly important for many patients with migraine who experience nausea and/or vomiting during an attack, which presents limitations for the use of oral therapies, including triptans, CGRP inhibitors and ditans as well as other non-specific medications used for the acute treatment of migraine.

    About Impel NeuroPharma:

    Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company's strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson's disease.

    Forward-Looking Statements

    This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, timing of approval of Impel's NDA for TRUDHESA™ and of Impel's other regulatory submissions, timing of announcements of clinical results and clinical development activities of its product candidates, potential benefits and market opportunities of TRUDHESA™ and its other product candidates and its cash runway. Forward-looking statements can be identified by words such as: "believe," "may," "will," "potentially," "estimate," "continue," "anticipate," "intend," "could," "would," "project," "plan," "expect" or the negative or plural of these words or similar expressions. These statements are subject to numerous risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including but not limited to, Impel's ability to obtain and maintain regulatory approval of TRUDHESA™ and its other product candidates, its ability to execute its commercialization strategy for TRUDHESA™, its ability to develop, manufacture and commercialize its product candidates including plans for future development of its POD devices and plans to address additional indications for which Impel may pursue regulatory approval, whether results of preclinical studies or clinical trials will be indicative of the results of future trials, and the effects of COVID-19 on its clinical programs and business operations. Many of these risks are described in greater detail in Impel's filings with the Securities and Exchange Commission. Any forward-looking statements in this press release speak only as of the date of this press release. Impel assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

          
     Impel Neuropharma, Inc.

    Condensed Consolidated Statement of Operations and Comprehensive Loss

    (in thousands, except share and per share amounts)
     
          
      For the three months ended March 31, 
       2021   2020  
     Operating expenses:    
     Research and development$4,098  $6,354  
     General and administrative 5,771   3,452  
     Total operating expenses 9,869   9,805  
     Loss from operations (9,869)  (9,805) 
     Interest income (expense), net (298)  33  
     Other expense, net (1,124)  14  
     Loss before income taxes (11,291)  (9,758) 
     Provision for income taxes    1  
     Net loss and comprehensive loss (11,291)  (9,759) 
     Accretion on redeemable convertible preferred stock 129   128  
     Net loss attributable to common stockholders$(11,420) $(9,887) 
          



        
           
     Impel Neuropharma, Inc.

    Condensed Consolidated Balance Sheets

    (in thousands, except share and per share amounts)
     
       March 31, 2021 December 31, 2020 
           
     Assets     
     Current assets:     
     Cash $4,467  $7,095  
     Prepaid expenses and other current assets  1,792   1,077  
     Total current assets  6,259   8,172  
     Property and equipment, net  3,512   3,700  
     Other assets  1,711   187  
     Total assets $11,482  $12,059  
     Liabilities, redeemable convertible preferred stock and stockholders' deficit     
     Current liabilities:     
     Accounts payable $6,425  $4,314  
     Accrued liabilities  2,625   3,173  
     Current portion of term debt  1,667   417  
     Redeemable convertible preferred stock warrant liabilities  2,677   2,622  
     Total current liabilities  13,394   10,526  
     Convertible notes at fair value  8,366   -  
     Long-term debt  6,963   7,994  
     Total liabilities $28,723  $18,520  
     Commitments and contingencies (Note 5)     
     Redeemable convertible preferred stock, $0.001 par value;

    204,198,489 shares authorized at March 31, 2021 and December 31,

    2020; 202,009,981 shares issued and outstanding at March 31, 2021

    and December 31, 2020; aggregate liquidation preference of

    $128,922 at March 31, 2021 and December 31, 2020
      127,168   127,039  
     Stockholders' deficit:     
     Common stock, $0.001 par value; 266,833,885 shares authorized

    at March 31, 2021 and December 31, 2020; 763,573 and 755,478

    shares issued and outstanding at March 31, 2021 and

    December 31, 2020, respectively
           
     Additional paid-in capital  5,144   4,762  
     Accumulated deficit  (149,553)  (138,262) 
     Total stockholders' deficit  (144,409)  (133,500) 
     Total liabilities, redeemable convertible preferred stock and stockholders' deficit $11,482  $12,059  
           



     Impel Neuropharma, Inc.

    Earnings Per Share

    (in thousands, except share and per share amounts)
     
      For the three months ended March 31, 
       2021   2020  
     GAAP Basic and Diluted EPS:    
     Numerator:    
     Net loss and comprehensive loss$(11,291) $(9,758) 
     Add: Accretion of preferred stock to redemption value 129   128  
     Net loss attributable to common shareholders$(11,420) $(9,886) 
     Denominator:    
     Common shares outstanding:    
     Weighted average common shares outstanding 756,986   360,808  
     Weighted average common shares outstanding, basic and diluted 756,986   360,808  
     Net loss per share attributable to common shareholders, basic and diluted$ (15.09) $ (27.40) 
          
          
      For the three months ended March 31, 
       2021   2020  
     Non-GAAP loss per share information:    
     Numerator:    
     Historical net loss attributable to common shareholders$(11,420) $(9,886) 
     Accretion of preferred stock to redemption value 129   128  
     Change in fair value of convertible notes 839   -  
     Change in fair value of redeemable convertible preferred stock warrant liabilities 55   (44) 
     Interest expense on convertible notes 27   -  
     Non-GAAP pro forma net loss attributable to common stockholders$(10,370) $(9,802) 
     Denominator:    
     Common shares outstanding:    
     Weighted average common shares outstanding 756,986   360,808  
     Shares issued in IPO 5,333,334   5,333,334  
     Common shares issued upon conversion of preferred stock 12,605,800   12,539,109  
     Automatic exchange of Avenue warrant 16,518   -  
     Issuance of shares of common stock pursuant to the net exercise of warrants 52,974   68,730  
     Shares issued upon conversion of convertible notes 559,585   -  
     Total Non-GAAP Pro Forma Loss per share attributable to common shareholders 19,325,197   18,301,981  
     Pro forma net loss per share attributable to common shareholders, basic and diluted$ (0.54) $ (0.54) 
          

    Contact

    Investor Relations:

    Christina Tartaglia

    Stern Investor Relations

    Phone: (1) 212-362-1200

    Email: 

    Media Relations:

    Melyssa Weible

    Elixir Health Public Relations

    Phone: (1) 201-723-5805

    Email: 



    Primary Logo

    View Full Article Hide Full Article
View All Impel NeuroPharma Inc. News